No monitoring for Vioxx-takers, court says

Slowly but surely Merck is working its way off the Vioxx hook. First, the successful fight-em-one-by-one strategy, then the big settlement, then a few key overturned verdicts--and now, the New Jersey Supreme Court has ruled that the drugmaker doesn't have to monitor Vioxx patients for future health problems. The 5-1 decision nullifies a class action lawsuit, filed by Vioxx users who don't have symptoms but wanted to be tested for any hidden problems.

The ruling states that patients can't pursue claims for medical monitoring unless they show "harm." Because these plaintiffs had no injuries to report, no harm done--in a legal sense, anyway.

- check out Merck's release
- read the Los Angeles Times story
- see the article in the Star-Ledger

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.